Homepage > Company > Media > Pharma News > 2024 > Recordati to acquire worldwide rights to Sanofi’s antibody Enjaymo

Recordati to acquire worldwide rights to Sanofi’s antibody Enjaymo

The strategic move is set to enhance Recordati's rare diseases franchise.

Recordati has reached an agreement with Sanofi for acquiring the worldwide rights to Enjaymo (Sutimlimab), the only approved treatment specifically targeting cold agglutinin disease (CAD), a rare B-cell lymphoproliferative disorder.

The terms of the acquisition include an upfront payment of $825m from Recordati to Sanofi, plus additional milestone payments of up to $250m contingent on sales performance.

This strategic move is set to enhance Recordati’s rare diseases franchise and address a critical unmet medical need.

The humanised monoclonal antibody Enjaymo is indicated to treat haemolysis in adults with CAD.

With approvals from the US Food and Drug Administration (FDA), European Commission, and the Japanese Ministry of Health, Labour and Welfare in 2022, Enjaymo offers a chronic intravenous treatment for this rare condition.

Over the last 12 months as of August 2024, Enjaymo generated revenue of approximately €100m ($110m) and is projected to generate more than €150m in financial year 2025, with peak sales potentially reaching €250-300m.

Enjaymo’s targeted mechanism of action inhibits the C1s in the classical complement pathway, preventing the abnormal breakdown of red blood cells.

The transaction is expected to close by the end of this year, pending regulatory approvals.

Read also

Sunvozertinib Granted Breakthrough Therapy Designation by China CDE for the First-Line Treatment of Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Dizal, a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced that the Center for Drug Evaluation (CDE) of China&...

FDA Approves Marstacimab-hncq for Adults, Adolescents With Hemophilia A or B Without Inhibitors

This approval marks the first and only anti-tissue factor pathway inhibitor approved in the US for the treatment hemophilia A or B, and the first approved hemophilia treatment to be administered via a...

Gilead gives up on $15M MASH bet with Yuhan after mulling preclinical data

In a year that has seen an approval and a raft of readouts for metabolic dysfunction-associated steatohepatitis (MASH), Gilead has decided to walk away from a $785 million biobucks deal in the...

FDA AdCom votes in favour of Stealth’s Barth syndrome drug

AUS Food and Drug Administration (FDA) advisory committee (AdCom) has voted in support of Stealth BioTherapeutics’ first-line Barth syndrome drug, despite a trial studying the drug n...